Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116512 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Sara Rodríguez-Mora und 12 weiteren Autor:innen. Beteiligte Einrichtung: Immunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; Biomedical Rese…. Hauptthemen laut MEDLINE: Dasatinib, HIV-1, Macrophages, HIV Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Agencia Estatal de Investigación, Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas.
Abstract (Originalsprache)
HIV-1 infection is efficiently controlled by the antiretroviral treatment (ART) but viral persistence in long-lived reservoirs formed by CD4 + T cells and macrophages impedes viral eradication and creates a chronic inflammatory environment. Dasatinib is a tyrosine kinase inhibitor clinically used against chronic myeloid leukemia (CML) that has also showed an anti-inflammatory potential. We previously reported that dasatinib is very efficient at interfering with HIV-1 infection of CD4 + T cells by preserving the antiviral activity of SAMHD1, an innate immune factor that blocks T-cell activation and proliferation and that is inactivated by phosphorylation at T592 (pSAMHD1). We observed that short-term treatment in vitro with dasatinib significantly reduced pSAMHD1 in monocyte-derived macrophages (MDMs) isolated from people with HIV (PWH) and healthy donors, interfering with HIV-1 infection. This inhibition was based on low levels of 2-LTR circles and proviral integration, while viral reverse transcription was not affected. MDMs isolated from people with CML on long-term treatment with dasatinib also showed low levels of pSAMHD1 and were resistant to HIV-1 infection. In addition, dasatinib decreased the inflammatory potential of MDMs by reducing the release of M1-related cytokines like TNFα, IL-1β, IL-6, CXCL8, and CXCL9, but preserving the antiviral activity through normal levels of IL-12 and IFNγ. Due to the production of M2-related anti-inflammatory cytokines like IL-1RA and IL-10 was also impaired, dasatinib appeared to interfere with MDMs differentiation. The use of dasatinib along with ART could be used against HIV-1 reservoir in CD4 and macrophages and to alleviate the chronic inflammation characteristic of PWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; Biomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de…
- Immunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; PhD Program in Biomedical Sciences and Public Health, Universidad Nacional de Educaci…
- Hematology and Hemotherapy Service, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
- Immunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
- Microscopy and Imaging Facility, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
- PhD Program in Health Sciences, Universidad de Alcalá, Madrid, Spain; Internal Medicine Service, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain.
Förderung
- NIAID NIH HHS
- Agencia Estatal de Investigación
- Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas
- European Regional Development Fund
- National Institutes of Health
- Ministerio de Ciencia e Innovación
- European Commission
- Cumming School of Medicine, University of Calgary
Zitieren
APA
Rodríguez-Mora, S., Sánchez-Menéndez, C., Bautista-Carrascosa, G., Mateos, E., Moreno-Serna, L., Megías, D., Cantón, J., García-Gutiérrez, V., Murciano-Antón, M. A., Cervero, M., Spivak, A., Planelles, V., & Coiras, M. (2024). Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116512
Vancouver
Rodríguez-Mora S, Sánchez-Menéndez C, Bautista-Carrascosa G, Mateos E, Moreno-Serna L, Megías D, et al. Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116512
BibTeX
@article{RodrguezMora2024,
author = {Rodríguez-Mora, Sara and Sánchez-Menéndez, Clara and Bautista-Carrascosa, Guiomar and Mateos, Elena and Moreno-Serna, Lucia and Megías, Diego and Cantón, Juan and García-Gutiérrez, Valentín and Murciano-Antón, María Aránzazu and Cervero, Miguel and Spivak, Adam and Planelles, Vicente and Coiras, Mayte},
title = {Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116512}
}
EUVIMED